Department of Child and Adolescent Psychiatry, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Center for Rare Endocrine Diseases, Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics and Adolescent Medicine, University Medical Center, Ulm, Germany.
Obes Facts. 2022;15(5):730-735. doi: 10.1159/000526169. Epub 2022 Aug 11.
Two psychiatric interviews of a 39-year old female with congenital leptin deficiency were conducted to define psychological changes 14 and 165 days after initiation of treatment with human recombinant leptin (metreleptin). The most pronounced initial experience related to the reduced preoccupation with food. An improved mood was reported by the patient, which she associated with this reduced preoccupation. Her mood remained elevated upon recontact, whereas she was no longer preoccupied with food. Overall, the interviews provide a vivid account of the subjective experiences upon the initiation of treatment. Some of the findings bear a resemblance to those reported recently in patients with anorexia nervosa who were treated with metreleptin for 1-3 weeks. This case report provides further evidence that metreleptin has strong psychopharmacological effects in patients with absolute or relative leptin deficiency. We strongly recommend profound psychological examinations of patients with congenital leptin deficiency at baseline and after intitiation of treatment with human recombinant leptin to gain further insight into the functions affected by this hormone.
对一位 39 岁的女性先天性瘦素缺乏症患者进行了两次精神病学访谈，以在开始用人重组瘦素（metreleptin）治疗 14 和 165 天后定义心理变化。最初最明显的体验与减少对食物的关注有关。患者报告说情绪有所改善，她将这种减少的关注与情绪改善联系起来。再次联系时，她的情绪仍然很高，而不再对食物着迷。总的来说，这些访谈生动地描述了治疗开始时的主观体验。一些发现与最近报道的接受 metreleptin 治疗 1-3 周的神经性厌食症患者的发现相似。本病例报告进一步证明 metreleptin 对绝对或相对瘦素缺乏症患者具有很强的精神药理学作用。我们强烈建议在先天性瘦素缺乏症患者的基线和开始接受人重组瘦素治疗后进行深入的心理检查，以进一步了解受这种激素影响的功能。
